Characterization of the in vitro activity of novel lipoglycopeptide antibiotics

Current Protocols in Microbiology

Volumn , Issue SUPPL. 16, 2010, Pages

  Arhin, Francis F ^a   Belley, Adam ^a   McKay, Geoffrey A ^a   Moeck, Gregory ^a  

^a The Medicines Company   (Canada)

Author keywords

Biofilm; Broth microdilution; Lipoglycopeptide; Macromolecular synthesis; Oritavancin; Synergy; Time kill

Indexed keywords

DALBAVANCIN; ORITAVANCIN; TELAVANCIN;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; BACTERIAL ENDOCARDITIS; BIOFILM; BROTH DILUTION; DEVICE INFECTION; ENTEROCOCCUS FAECALIS; GROWTH INHIBITION; MEMBRANE POTENTIAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOFILMS; GLYCOPEPTIDES; LIPOPEPTIDES; MEMBRANE POTENTIALS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS;

EID: 77949342696     PISSN: 19348525     EISSN: 19348533     Source Type: Journal    
DOI: 10.1002/9780471729259.mc1701s16     Document Type: Review

References (21)

1. Alborn, W.E. Jr., Allen, N.E., and, Preston, D.A., 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35: 2282 - 2287.
2. Anderegg, T.R., Biedenbach, D.J., and, Jones, R.N., 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J. Clin. Microbiol. 41: 2795 - 2796.
3. Arhin, F.F., Sarmiento, I., Parr, T.R. Jr., and, Moeck, G., 2007. Mechanisms of action of oritavancin in Staphylococcus aureus. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois. September 17-20, 2007. Poster no. C1-1471.
4. Arhin, F.F., Sarmiento, I., Belley, A., McKay, G.A., Draghi, D.C., Grover, P., Sahm, D., Parr, T.R. Jr., and, Moeck, G., 2008a. Effect of polysorbate-80 on oritavancin binding to plastic surfacesImplications for susceptibility testing. Antimicrob. Agents Chemother. 52: 1597 - 1603.
5. Arhin, F.F., Tomfohrde, K., Draghi, D.D., Aranza, M., Parr, T.R. Jr., Sahm, D.F., and, Moeck, G., 2008b. Newly-defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diag. Microbiol. Infec. Dis. 62: 92 - 95.
6. Arhin, F.F., Sarmiento, I., Parr, T.R. Jr., and, Moeck, G., 2008c. Binding of oritavancin to surfaces impacts choice of vessels for oritavancin in vitro assays. 58th Annual meeting of the Canadian Society of Microbiologists; Calgary, Alberta, June 9-12, 2007. Poster no. B1.
7. Belley, A., Neesham-Grenon, E., Arhin, F.F., McKay, G.A., Parr, T.R. Jr., and, Moeck, G., 2008. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 3820 - 3822.
8. Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F.F., Harris, R., Beveridge, T., Parr, T.R. Jr., and, Moeck, G., 2009. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53: 918 - 925.
9. Blosser, R.S., Karlowsky, J.A., Loutit, J.S., Porter, S.B., Jones, M.E., Thornsberry, C., and, Sahm, D.F., 2003. Evaluation of agar-based susceptibility testing of oritavancin against Gram-positive cocci. 103rd General Meeting of the American Society for Microbiology, Washington, D.C., Poster no. C-70.
10. Clinical and Laboratory Standards Institute. 2009a. Performance standards for antimicrobial susceptibility testing, 19th information supplement. M100-S19. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania.
11. Clinical and Laboratory Standards Institute. 2009b. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard, 8th edition. M7-A8. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania.
12. Higgins, D.L., Chang, R., Debabov, D.V., Leung, J., Wu, T., Krause, K.M., Sandvik, E., Hubbard, J.M., Kaniga, K., Schmidt, D.E., Gao, Q., Cass, R.T., Karr, D.E., Benton, B.M., and, Humphrey, P.P., 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 1127 - 1134.
13. Kaito, C., Kurokawa, K., Hossain, M.S., Akimitsu, N., and, Sekimizu, K., 2002. Isolation and characterization of temperature-sensitive mutants of the Staphylococcus aureus dnaC gene. FEMS Microbiol. Lett. 210: 157 - 164.
14. Kreiswirth, B.N., Lofdahl, M.S., Betley, M.J., OReilly, M., Schlievert, P.M., Bergdoll, M.S., and, Novick, R.P., 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305: 709 - 712.
15. Krogstad, D., and, Moellering, R. Jr., 1986. Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 2nd ed. (, V. Lorian, ed.) pp. 432 - 492. Williams and Wilkins, Baltimore, Maryland.
16. McKay, G.A., Beaulieu, S., Arhin, F.F., Belley, A., Sarmiento, I., Parr, T.R. Jr., and, Moeck, G., 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63: 1191 - 1199.
17. McKay, G.A., Fadhil, I., Beaulieu, S., Ciblat, S., Rafai, Far A., Moeck, G., and, Parr, T.R. Jr., 2006. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant Enterococci. 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. September 27-30, 2006. Poster no. C1-682.
18. National Committee on Clinical Laboratory Standards. 1999. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. NCCLS document M26-A [ISBN 1-56238-384-1]. NCCLS, Wayne, Pennsylvania.
19. Reynolds, P.E., 1989. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect Dis. 8: 943 - 950.
20. Rybak, M.J., 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42: S35 - S39.
21. Silverman, J.A., Perlmutter, N.G., and, Shapiro, H.M., 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 2538 - 2544.